Every skin type has its own specific needs. Select your concern and get the dermatological advice and skincare solutions you need.
REBALANCES YOUR SKIN MICROBIOME.
PROVIDES A TRIPLE-REPAIR EFFICACY
FOR ATOPIC ECZEMA-PRONE SKIN.
Our life-changing range is reinventing its iconic product, LIPIKAR Baume AP+,
With a new exclusive AP+M technology [Aqua Posae + Microresyl] that rebalances microbiome
by limiting the multiplication and persistence of Staph bacteria involved in eczema.
Daily applied, it spaces out flare-ups of severe dryness for a reinforced anti-relapse efficacy.
WHAT IS THE MICROBIOME?
The microbiome is the invisible ecosystem of microorganisms living on your skin.
A balanced microbiome promotes good skin health.
Excessive overgrowth of Staphylococus bacteria.
Balanced quantity and diversity of microorganisms on your skin.
THE FIGHT AGAINST
VERY DRY AND ECZEMA-PRONE SKIN
STARTS FROM WITHIN
With its reinforced triple-repair efficacy, Lipikar Baume AP+M provides immediate soothing, with an anti-scratching and anti-relapse effect. A stronger microbiome to better face skin discomfort and scratching.
THROUGH 7 CLINICAL STUDIES
Study conducted on 45 adult subjects with atopy-prone skin. 14 days of application of Lipikar Baume AP+M, once or twice per day.
Study conducted on 99 subjects (babies, children, adults) with atopy-prone skin. 8 weeks.
Pain evaluation on D 0 and after 2 days of Lipikar Baume AP+M usage. 45 adult subjects with atopy-prone skin.
AND GREAT TOLERANCE.
LIPIKAR BAUME AP+M, tested under dermatological and pediatric control on adults, children and babies.
- 100% were satisfied by the new Baume AP+M*
- 96% found it better than their usual product
* Clinical study conducted on 54 women, between 18-60 years old, eczema, daily use on body and face for 28 days.
LIPIKAR BAUME AP+M:
A STRONGER FORMULA
Effectiveness and high tolerance for the new formula of LIPIKAR Baume AP+M.
LIPIKAR, THE ANTI-ITCHING ROUTINE
FOR ECZEMA-PRONE SKIN
THE LIPIKAR WINNING TRIO
ABOUT ECZEMA SKIN
and July 2019 among dermatologists in 43 countries representing more than 80% of the worldwide GDP